Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
11,549,491
-
Number of holders
-
39
-
Total 13F shares, excl. options
-
3,255,627
-
Shares change
-
-87,964
-
Total reported value, excl. options
-
$3,776,528
-
Value change
-
-$96,760
-
Put/Call ratio
-
0%
-
Number of buys
-
8
-
Number of sells
-
-10
-
Price
-
$1.16
Significant Holders of TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share (TXMD) as of Q2 2025
44 filings reported holding TXMD - TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share as of Q2 2025.
TherapeuticsMD, Inc. - Common Stock, par value $0.001 per share (TXMD) has 39 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 3,255,627 shares
of 11,549,491 outstanding shares and own 28% of the company stock.
Largest 10 shareholders include Rubric Capital Management LP (1,192,191 shares), Clearline Capital LP (635,222 shares), VANGUARD GROUP INC (379,001 shares), Tejara Capital Ltd (344,254 shares), ADAR1 Capital Management, LLC (209,210 shares), MORGAN STANLEY (131,210 shares), BlackRock, Inc. (116,132 shares), GEODE CAPITAL MANAGEMENT, LLC (109,083 shares), BRIDGEWAY CAPITAL MANAGEMENT, LLC (34,000 shares), and STATE STREET CORP (30,100 shares).
This table shows the top 39 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.